Application routes for 4-[[(4-Fluorophenyl)imino]methyl]-phenol Pharma Grade API are assessed against compendial and current GMP requirements. No commercial monograph for this specific molecular entity has been identified in public pharmacopoeial databases. Formulation parameters are therefore reported as development starting ranges, not as licensed product specifications.

Moisture-controlled direct compression is evaluated first because the azomethine linkage in 4-[[(4-Fluorophenyl)imino]methyl]-phenol is sensitive to aqueous acidic processing and because the free phenol can interact with non-passivated metal surfaces under elevated humidity. A starting blend comprising 10–20 wt% micronized API, 55–65 wt% microcrystalline cellulose NF, 15–20 wt% anhydrous lactose NF, 2–4 wt% crospovidone USP/NF, 0.5–1.0 wt% colloidal silicon dioxide NF, and 0.75–1.25 wt% magnesium stearate NF is screened in a 316L stainless steel contact system. Each excipient lot is pre-conditioned at 25 °C and ≤40% RH. The API is passed through a 600 µm sieve. Blending is performed in a bin blender at 15 rpm for 15–20 min, with lubricant added separately for the final 3 min to prevent shear-induced agglomeration. Compression is run on a 27-station rotary tablet press with D-tooling. Press force is held at 10–25 kN depending on tablet diameter and fill depth. Tablet hardness is monitored at 60–100 N; friability is controlled to ≤1.0% after 100 revolutions according to USP <1216>. Disintegration is tested in 900 mL water at 37±2 °C under USP <701>. Content uniformity is assessed by HPLC with acceptance value AV≤15.0 under USP <905>. Elemental impurity risk is controlled per ICH Q3D and 21 CFR 211.166. The terminal product is an immediate-release uncoated tablet with development batch sizes from 50 kg to 300 kg. Process boundary: if ambient RH exceeds 60%, equilibrium moisture uptake reduces powder flow and may increase punch sticking; direct compression is then suspended and dry granulation is considered. Published data for this specific compound at commercial scale is limited.

What Is the Control Range for Roll-Compacted Ribbon Density Before Capsule Fill?

Roller compaction is introduced when direct compression blend flow is insufficient or when the API particle size distribution creates segregation risk. Dry granulation avoids water exposure and is therefore compatible with the hydrolytically labile imine function. A starting intragranular blend contains 20 wt% API, 45 wt% microcrystalline cellulose NF, 20 wt% anhydrous dibasic calcium phosphate USP/NF, 3 wt% crospovidone USP/NF, 1 wt% colloidal silicon dioxide NF, and 1 wt% magnesium stearate NF. Extragranular components are 2 wt% crospovidone and 0.5 wt% sodium stearyl fumarate NF. The mixture is compacted on a production-scale roller compactor with 0.8–1.5 mm roller gap and roll pressure 4–12 kN/cm. Ribbon envelope density is maintained between 1.10 g/cm³ and 1.45 g/cm³; above this range, granule tabletability decreases and in vitro dissolution slows, while below this range, excessive fines reduce capsule filling consistency. Milling is performed through a 1.0 mm screen to produce granule size of 150–710 µm. Capsule filling uses a production-scale dosator or tamping pin machine targeting fill weight 200–250 mg for size 3 hard gelatin or HPMC capsules. Fill weight variation is checked with USP <905>. Powder flow is characterized using USP <1174>; Carr index below 25 and Hausner ratio below 1.25 are preferred. In vitro dissolution is performed with USP <711> apparatus 1 at 100 rpm in 900 mL phosphate buffer at pH 6.8±0.05. The terminal product is a hard capsule containing 25 mg or 50 mg API. Process boundary: re-compaction of recycled ribbons can raise fines below 15% but increases apparent density; the maximum recycle fraction is limited to 15–20 wt% of the total granulate. Published data for this specific configuration is limited.

The aqueous suspension route is treated as a separate stability case because the wetting step provides intimate water contact and the imine hydrolysis rate depends strongly on pH and dissolved oxygen. The micronized API is wet-milled or jet-milled to a controlled particle size with D90 ≤10 µm to reduce sedimentation. A preservative-free or preserved vehicle is prepared with xanthan gum 0.25–0.5 wt%, microcrystalline cellulose/sodium carboxymethylcellulose NF 1.0–2.0 wt%, sorbitol solution 10–20 wt%, methylparaben 0.1–0.2 wt%, and propylparaben 0.01–0.02 wt%. The pH is adjusted with sodium hydroxide or tromethamine to 6.8–7.2. API is incorporated as a slurry containing polysorbate 80 0.02–0.05 wt%. Homogenization is conducted at 1500–3000 rpm for 10–15 min. The suspension is filled into amber polyethylene terephthalate bottles under a nitrogen overlay to reduce dissolved oxygen below 0.5 mg/L. Antimicrobial effectiveness is evaluated under USP <51>; deliverable volume is checked under USP <698>; pH stability is monitored with a calibrated pH meter. The terminal product is an oral suspension at 5 mg/mL in a 60 mL bottle with a beyond-use date of 30 days under 2–8 °C storage. Process boundary: pH excursion below 5.0 is considered prohibitive because acid-catalyzed hydrolysis of the imine bond would generate 4-fluorobenzenamine and 4-hydroxybenzaldehyde. Trace copper and iron must be controlled by using passivated equipment and, if needed, disodium edetate at 0.005–0.01 wt% to suppress metal-catalyzed degradation. Published data for this specific configuration is limited.

When the Phenol Moiety Is Ionized for Freeze-Dried Injectable Cakes

For parenteral administration, the phenol function is ionized to a soluble phenolate in Water for Injection. The starting solution contains API at 5–20 mg/mL, mannitol at 30–50 mg/mL, and tromethamine for pH adjustment to 7.4–8.0. Trehalose dihydrate at 20–40 mg/mL may be evaluated as an alternative cryoprotectant when mannitol crystallization causes cake collapse. The solution is prepared in a 316L stainless steel vessel under nitrogen sparging. Pre-filtration is performed through a 0.45 µm PVDF filter, followed by sterilizing filtration through a 0.22 µm PES filter. Filling is performed aseptically into Type I borosilicate glass vials with bromobutyl rubber stoppers. Lyophilization is initiated with shelf freezing at -40 °C for 2 h, followed by primary drying at -20 °C and chamber pressure 50–100 µbar, and secondary drying at 25 °C for 8–12 h. Residual water is controlled below 1.0% w/w by Karl Fischer titration. The terminal product is a lyophilized powder in a 10R vial reconstituted to 10 mL before administration. Terminal steam sterilisation is not applicable because the azomethine linkage is expected to hydrolyze under autoclave conditions; aseptic processing is therefore mandatory for this dosage form.

High-Shear Wet Granulation with Non-Aqueous Binder Systems

Wet granulation is limited to non-aqueous or low-water binder systems for this compound. Anhydrous ethanol or isopropanol is used as the granulation fluid to minimize water activity. A starting formulation contains API 10–15 wt%, lactose monohydrate NF 60–70 wt%, microcrystalline cellulose NF 10–15 wt%, croscarmellose sodium USP/NF 2–4 wt%, and povidone K30 dissolved in anhydrous ethanol at 3–5 wt% solids. Granulation is performed in a high-shear granulator with impeller speed 200–400 rpm, binder addition rate 0.5–1.0 kg/min, and wet massing time 2–4 min. Drying is conducted in a fluid-bed dryer with inlet air temperature 50–60 °C and product temperature held at ≤45 °C. Loss on drying after granulation is controlled at ≤2.0% w/w. The dried granulate is milled through a 1.0 mm screen and compressed into tablets for film coating. Residual solvent is controlled under USP <467> and ICH Q3C; ethanol is limited as a Class 3 solvent at ≤5000 ppm. Tablet friability is assessed under USP <1216> and disintegration under USP <701>. The terminal product is a film-coated tablet with a hydroxypropyl methylcellulose-based moisture barrier coating applied at 2–3 wt% weight gain. Process boundary: if water activity during drying exceeds 0.5, localized imine hydrolysis can occur; therefore drying endpoints are confirmed by Karl Fischer titration and not solely by outlet temperature. Published data for this specific configuration is limited.